Echocardiography: Left ventricular hypertrophy and atherosclerosis

Non-Invasive Surrogate Markers of Atherosclerosis

Volumn , Issue , 2008, Pages 1-9

  Liebson, Philip R ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878461548     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (51)

1. Shimizu G, Hirota Y, Kita Y et al. Left ventricular midwall mechanics in systemic arterial hypertension. Circulation 1991; 83: 1676-84.
2. Voci P, Pizzuto F, Romeo F. Coronary flow: a new asset for the echo lab? Eur Heart J 2004; 35: 1867-79.
3. Levy D, Anderson KM, Savage DD et al. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Int Med 1988; 108: 7.
4. Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561.
5. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848-56.
6. East MA, Jollis JG, Nelson CL et al. The influence of left ventricular hypertrophy on survival in patients with coronary artery disease: do race and gender matter? J Am Coll Cardiol 2003; 41: 949-54.
7. Sundström J, Lind L, Ärnlöv J et al. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001; 103: 2346.
8. Hammond IW, Devereux RB, Alderman MH et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7: 639-50.
9. Sukhija R, Aranow WS, Kakar P et al. Prevalence of echocardiographic left ventricular hypertrophy in persons with systemic hypertension, coronary artery disease, and peripheral arterial disease and in persons with systemic hypertension, coronary artery disease, and no peripheral arterial disease. Am J Cardiol 2005; 96: 825-26.
10. Ghali JK, Liao Y, Cooper RS. Influence of left ventricular geometric patterns on prognosis in patients with or without coronary artery disease. J Am Coll Cardiol 1998; 31: 1635.
11. Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Int Med 1991; 114: 345.
12. Gardin JM, Iribarren C, Detrano RC et al. The relation of echocardiographic left ventricular mass, geometry and wall stress, and left atrial dimension to coronary calcium in young adults (The CARDIA study). Am J Cardiol 2005; 95: 626-9.
13. Altunkan S, Erdogan N, Altin L, Budoff MJ. Relation of coronary artery calcium to left ventricular mass and geometry in patients with essential hypertension. Blood Pressure Monitoring 2003; 8: 9-15.
14. Lorell BH, Carabello BA. Left ventricular hypertrophy. Pathogenesis, detection, and prognosis. Circulation 2000; 102: 470-9.
15. Kuroda YT, Komamura K, Tatsumi R et al. Vascular cell adhesion molecule-1 as a biochemical marker of left ventricular mass in patients with hypertension. Am J Hypertens 2001; 14: 868-72.
16. Perticone F, Ceravolo R, Pujia A et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191.
17. Treasure CB, Klein L, Vita JA et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993; 87: 86-93.
18. Houghton JL, Strogatz DS, Torosoff, MT et al. African-Americans with LVH demonstrate depressed sensitivity of the coronary microvasculature to structural relaxation. Hypertension 2003; 42: 269-76.
19. Schwartzkopff B, Motz W, Frenzel H et al. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88: 993-1003.
20. Lip GY, Blann AD, Jones AF et al. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566.
21. Bader M. Role of the local renin-angiotensin system in cardiac damage: a minireview focusing on transgenic animal models. J Mol Cell Cardiol 2002; 34: 1455-62.
22. Dong Y, Wang X, Zhu H et al. Endothelin-1 gene and progression of blood pressure and left ventricular mass: longitudinal findings in youth. Hypertension 2004; 44: 884-90.
23. MacCarthy PA, Grieve DA, Li J-M et al. Impaired endothelial cell regulation of ventricular relaxation in cardiac hypertrophy. Role of reactive oxygen species and NADPH oxidase. Circulation 2001; 104: 2967.
24. Frey N, Olson EN. Modulating cardiac hypertrophy by manipulating myocardial lipid metabolism? Circulation 2002; 105: 1152-4.
25. Jamshidi Y, Montgomery HE, Hense H-W et al. Peroxisome proliferators-activated receptor α gene regulates left ventricular growth in response to exercise and hypertension. Circulation 2000; 103: 226-30.
26. Kelly DP. Peroxisome proliferators-activated receptor α as a genetic determinant of cardiac hypertrophic growth. Culprit or innocent bystander? Circulation 2002; 105: 1025-27.
27. Barger PM, Brandt JM, Leone TC et al. Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J Clin Invest 2000; 105: 1723-30.
28. Frey N, Katus HA, Olsen EN, Hill JA. Hypertrophy of the heart. A new therapeutic target? Circulation 2004; 109: 1580-9.
29. Asakawa M, Takano H, Nagai T et al. Peroxisome proliferator-activated receptor γ plays a critical role in the inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002; 105: 1240-6.
30. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002; 287: 360-72.
31. Dawson A, Orrius AD, Struthers AD. The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia 2005; 48: 1971-9.
32. Hill D, Millner D. Insulin as a growth factor. Pediatr Res 1985; 19: 879-86.
33. Adachi A, Ito H, Akimoto H et al. Insulin-like growth factor-II induces hypertrophy with increased expression of muscle-specific genes in cultured rat myocytes. J Mol Cell Cardiol 1994; 26: 789-95.
34. Sader S, Nian M, Liu P. Leptin. A novel link between obesity, diabetes, cardiovascular risk, and ventricular hypertrophy. Circulation 2003; 108: 644-6.
35. Barouch LA, Berkowitz DE, Harrison RW et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003; 108: 754-9.
36. Molkentin JD, Olsen EN. GATA-4: A novel transcriptional regulator of cardiac hypertrophy? Circulation 1997; 96: 3833-5.
37. Dimitrow PP, Galderisi M, Rigo F. The non-invasive documentation of coronary microcirculation impairment: role of transthoracic echocardiography. Cardiovasc Ultrasound 2005: 3: 18-26.
38. Kozàkovà M, de Simone G, Morizzo C, Palombo C. Coronary vasodilator capacity and hypertension-induced increase in left ventricular mass. Hypertension 2003; 41: 224.
39. Marcus ML, Koyanagi S, Harrison DG, et al. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am J Med 1983; 75: 62-6.
40. Palmieri V, Storto G, Arezzi E et al. Relations of left ventricular mass and systolic function to endocardial function and coronary flow reserve in healthy, new discovered hypertensive subjects. J Hum Hypertens 2005; 10: 1-10.
41. Gimelli A, Schneider-Eicke J, Neglia D et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with the degree of hypertrophy. J Am Coll Cardiol 1998; 31: 366.
42. Roman MJ, Pickering TG, Schwartz JE et al. Relation of arterial structure and function to left ventricular geometric patterns in hypertensive adults. J Am Coll Cardiol 1996; 28: 751-6.
43. Strauer BE, Schwartzkopff B. Objectives of high blood pressure treatment: left ventricular hypertrophy, diastolic function, and coronary reserve. Am J Hypertens 1998; 11: 879-81.
44. Kataoka T, Hamasaki S, Ishida S et al. Contribution of increased minimal coronary resistance and attenuated vascular adaptive remodeling to myocardial ischemia in patients with systemic hypertension and ventricular hypertrophy. Am J Cardiol 2004; 94: 484-7.
45. Laine H, Katoh C, Luotolahti M et al. Myocardial oxygen consumption is unchanged but efficiency is reduced in patients with essential hypertension and left ventricular hypertrophy. Circulation 1999; 100: 2425.
46. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.
47. Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Relation of blood pressure variability to carotid atherosclerosis and carotid artery and left ventricular hypertrophy. Arterioscler Thromb Vasc Biol 2001; 21: 1507-11.
48. Roman MJ, Devereux RB, Schwartz JE et al. Arterial stiffness in chronic inflammatory diseases. Hypertension 2005; 46: 194-9.
49. Yildiz A, Memisoglu E, Oflaz H et al. Atherosclerosis and vascular calcification are independent predictors of left ventricular hypertrophy in chronic hemodialysis patients. Nephrol Dial Transplant 2005; 20: 760-7.
50. Chen CH, Ting CT, Lin, SJ et al. Which arterial and cardiac parameters best predict left ventricular mass? Circulation 1998; 98: 422-8.
51. Safar ME, Levy BI, Struijker-Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864-9.